Substituted {5-methoxy-6-[(5-methoxypyridin-2-yl)methoxy]pyridin-3-yl} methyl compounds as CSF-1R inhibitors
The present invention provides a compound of Formula I: Formula I or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the compound and to methods of using the compound to treat physiological disorders.
1 . A compound of the formula:
or a pharmaceutically acceptable salt thereof.
2 . A method of treating Alzheimer's disease in a patient in need thereof, comprising administering to the patient an effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof.
3 . A pharmaceutical composition, comprising an effective amount of the compound, or a pharmaceutically acceptable salt thereof, of claim 1 and one or more pharmaceutically acceptable carrier, diluent, or excipient.
4 . A process for preparing a pharmaceutical composition, comprising admixing the compound, or a pharmaceutically acceptable salt thereof, of claim 1 with one or more pharmaceutically acceptable carrier, diluent, or excipient.
5 . A compound of the formula:
6 . A pharmaceutical composition comprising an effective amount of the compound of claim 5 and one or more pharmaceutically acceptable carrier, diluent, or excipient.
7 . A process for preparing a pharmaceutical composition, comprising admixing the compound of claim 5 with one or more pharmaceutically acceptable carriers, diluents, or excipients.
8 . A method of treating Alzheimer's disease in a patient in need thereof, comprising administering to the patient an effective amount of the compound of claim 5 .